Objective: The aims of this study were as follows: 1) to evaluate the association of serum sclerostin with bone mineral density (BMD) and markers of bone metabolism in postmenopausal Chinese women and 2) to observe the relationships of single-nucleotide polymorphisms (SNPs) within the sclerostin (SOST) gene with serum sclerostin, BMD, and markers of bone metabolism.
Design: A cross-sectional study was conducted with 703 postmenopausal Chinese women. Ten tagging SNPs (rs1234612, rs1513670, rs1634330, rs1708635, rs2023794, rs7220711, rs74252774, rs851057, rs851058, and rs865429) of the SOST gene were genotyped. Serum sclerostin and markers of bone metabolism were measured, including serum intact PTH, 25-hydroxyvitamin D [25(OH)D], procollagen type 1 N-terminal propeptide, and β-CrossLaps of type I collagen containing cross-linked C-telopeptide (β-CTX). The BMD of the lumbar spine and proximal femur were measured by dual-energy X-ray absorptiometry.
Results: Serum sclerostin was positively correlated with BMD at the lumbar spine, femoral neck, and total hip and with serum 25(OH)D (all P < .01) but negatively correlated with β-CTX (P < .01). The significant relationships between serum sclerostin and BMD and with serum β-CTX persisted, even after adjustments for age, body mass index, and serum 25(OH)D (all P < .01). However, there was no correlation between serum sclerostin and age or serum procollagen type 1 N-terminal propeptide. We failed to identify a significant association between the SNP, haplotypes of SOST and BMD, or serum sclerostin.
Conclusion: Our results suggested that serum sclerostin was positively correlated with the BMD at the lumbar spine, femoral neck, and total hip and with serum 25(OH)D but was negatively correlated with serum β-CTX. Genetic polymorphisms of SOST may not be a major contributor to variations in the serum sclerostin or BMD in postmenopausal Chinese women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2013-2086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The serum level of sclerostin decreases in radiographic axial spondyloarthritis patients with fatty lesions.
Arthritis Res Ther
January 2025
Department of Rheumatology, the Fifth Affiliated Hospital of Sun Yat-sen University, 52 Meihua East Road, Zhuhai, People's Republic of China.
Background: Currently, the pathophysiology of new bone formation in radiographic axial spondyloarthritis (r-axSpA) remains unclear. Cellular elements and their secreted bone turnover markers might be one of the underlying mechanisms that drive the new bone formation. Our study aimed to investigate the role of bone turnover markers in r-axSpA patients with fatty lesions.
View Article and Find Full Text PDFSclerostin as a new target of diabetes-induced osteoporosis.
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology and Metabolism, Want Want Hospital, Changsha, Hunan, China.
Sclerostin, a protein synthesized by bone cells, is a product of the gene. Sclerostin is a potent soluble inhibitor of the WNT signaling pathway, and is known to inhibit bone formation by inhibiting osteocyte differentiation and function. Currently, sclerostin has been the subject of numerous animal experiments and clinical investigations.
View Article and Find Full Text PDFShort-term effects of dapagliflozin on biomarkers of bone and mineral metabolism in patients with diabetic kidney disease: A prospective observational study.
Nefrologia (Engl Ed)
December 2024
Division of Nephrology, Department of Internal Medicine, Bezmialem Vakif University School of Medicine, Istanbul, Turkey. Electronic address:
Background: There is still a lack of information regarding the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on bone and mineral metabolism in patients with diabetes and chronic kidney disease (CKD). Therefore, we aimed to investigate the effects of SGLT2i in a cohort of patients suffering from diabetic kidney disease (DKD).
Methods: In this prospective observational study, patients with type 2 diabetes and biopsy-proven diabetic nephropathy or presumptive DKD with eGFR levels ≥20 ml/min/1.
Health implications of racial differences in serum growth differentiation factor levels among men with obesity.
Physiol Rep
December 2024
Division of Endocrinology Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas, USA.
Article Synopsis
- The study examined the role of Growth differentiation factor (GDF15) in relation to health markers in obese men of different racial and ethnic backgrounds.
- It involved 193 participants and assessed various health metrics including body composition, hormonal levels, and bone mineral density.
- Findings indicated that GDF15 levels were higher in non-African Americans than in African Americans, and its relations to glucometabolic status and body composition varied by ethnicity, highlighting potential racial differences in health risks.
Effect of vitamin D3, omega-3 fatty acids, and exercise on serum sclerostin levels and bone turnover markers.
J Clin Endocrinol Metab
December 2024
Department of Medicine III and Technische Universität Dresden, Dresden, Germany.
Context: Sclerostin inhibits canonical Wnt signaling, a pathway promoting bone formation. The effects of vitamin D3, omega-3 fatty acids (omega-3s), and exercise on serum sclerostin levels and bone metabolism are unclear.
Objective: To investigate the effects of 2000 IU/d vitamin D3, 1g/d omega-3s, and a simple home-based strength exercise program (SHEP), alone or in combination, on serum sclerostin and bone turnover marker levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!